Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 239

1.

Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications.

Mosquera JM, Perner S, Genega EM, Sanda M, Hofer MD, Mertz KD, Paris PL, Simko J, Bismar TA, Ayala G, Shah RB, Loda M, Rubin MA.

Clin Cancer Res. 2008 Jun 1;14(11):3380-5. doi: 10.1158/1078-0432.CCR-07-5194.

2.

Expression of ERG protein, a prostate cancer specific marker, in high grade prostatic intraepithelial neoplasia (HGPIN): lack of utility to stratify cancer risks associated with HGPIN.

He H, Osunkoya AO, Carver P, Falzarano S, Klein E, Magi-Galluzzi C, Zhou M.

BJU Int. 2012 Dec;110(11 Pt B):E751-5. doi: 10.1111/j.1464-410X.2012.11557.x. Epub 2012 Oct 9.

3.

TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia.

Park K, Dalton JT, Narayanan R, Barbieri CE, Hancock ML, Bostwick DG, Steiner MS, Rubin MA.

J Clin Oncol. 2014 Jan 20;32(3):206-11. doi: 10.1200/JCO.2013.49.8386. Epub 2013 Dec 2.

4.

Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer.

Furusato B, Gao CL, Ravindranath L, Chen Y, Cullen J, McLeod DG, Dobi A, Srivastava S, Petrovics G, Sesterhenn IA.

Mod Pathol. 2008 Feb;21(2):67-75. Epub 2007 Dec 7.

5.

TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions.

Cerveira N, Ribeiro FR, Peixoto A, Costa V, Henrique R, Jerónimo C, Teixeira MR.

Neoplasia. 2006 Oct;8(10):826-32.

6.

Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization.

Haffner MC, Weier C, Xu MM, Vaghasia A, Gürel B, Gümüşkaya B, Esopi DM, Fedor H, Tan HL, Kulac I, Hicks J, Isaacs WB, Lotan TL, Nelson WG, Yegnasubramanian S, De Marzo AM.

J Pathol. 2016 Jan;238(1):31-41. doi: 10.1002/path.4628. Epub 2015 Oct 14.

7.

ETS gene aberrations in atypical cribriform lesions of the prostate: Implications for the distinction between intraductal carcinoma of the prostate and cribriform high-grade prostatic intraepithelial neoplasia.

Han B, Suleman K, Wang L, Siddiqui J, Sercia L, Magi-Galluzzi C, Palanisamy N, Chinnaiyan AM, Zhou M, Shah RB.

Am J Surg Pathol. 2010 Apr;34(4):478-85. doi: 10.1097/PAS.0b013e3181d6827b.

PMID:
20220513
8.

ERG rearrangement for predicting subsequent cancer diagnosis in high-grade prostatic intraepithelial neoplasia and lymph node metastasis.

Gao X, Li LY, Zhou FJ, Xie KJ, Shao CK, Su ZL, Sun QP, Chen MK, Pang J, Zhou XF, Qiu JG, Wen XQ, Yang M, Bai XZ, Zhang H, Ling L, Chen Z.

Clin Cancer Res. 2012 Aug 1;18(15):4163-72. Epub 2012 Jun 13.

9.

Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.

Mosquera JM, Mehra R, Regan MM, Perner S, Genega EM, Bueti G, Shah RB, Gaston S, Tomlins SA, Wei JT, Kearney MC, Johnson LA, Tang JM, Chinnaiyan AM, Rubin MA, Sanda MG.

Clin Cancer Res. 2009 Jul 15;15(14):4706-11. doi: 10.1158/1078-0432.CCR-08-2927. Epub 2009 Jul 7.

10.

Role of the TMPRSS2-ERG gene fusion in prostate cancer.

Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, Cao Q, Prensner JR, Rubin MA, Shah RB, Mehra R, Chinnaiyan AM.

Neoplasia. 2008 Feb;10(2):177-88.

11.

The incidence of high-grade prostatic intraepithelial neoplasia and atypical glands suspicious for carcinoma on first-time saturation needle biopsy, and the subsequent risk of cancer.

Schoenfield L, Jones JS, Zippe CD, Reuther AM, Klein E, Zhou M, Magi-Galluzzi C.

BJU Int. 2007 Apr;99(4):770-4. Epub 2007 Jan 16.

12.

High grade prostatic intraepithelial neoplasia does not display loss of heterozygosity at the mutation locus in BRCA2 mutation carriers with aggressive prostate cancer.

Willems-Jones A, Kavanagh L, Clouston D, Bolton D; kConFab Investigators, Fox S, Thorne H.

BJU Int. 2012 Dec;110(11 Pt C):E1181-6. doi: 10.1111/j.1464-410X.2012.11519.x. Epub 2012 Oct 4.

14.

Risk of prostate cancer after detection of isolated high-grade prostatic intraepithelial neoplasia (HGPIN) on extended core needle biopsy: a UK hospital experience.

Singh PB, Nicholson CM, Ragavan N, Blades RA, Martin FL, Matanhelia SS.

BMC Urol. 2009 May 27;9:3. doi: 10.1186/1471-2490-9-3.

15.

Clinical applications of novel ERG immunohistochemistry in prostate cancer diagnosis and management.

Shah RB.

Adv Anat Pathol. 2013 Mar;20(2):117-24. doi: 10.1097/PAP.0b013e3182862ac5. Review.

PMID:
23399797
16.

Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies.

Tomlins SA, Palanisamy N, Siddiqui J, Chinnaiyan AM, Kunju LP.

Arch Pathol Lab Med. 2012 Aug;136(8):935-46. doi: 10.5858/arpa.2011-0424-OA.

18.

Chromosome mechanisms giving rise to the TMPRSS2-ERG fusion oncogene in prostate cancer and HGPIN lesions.

Teixeira MR.

Am J Surg Pathol. 2008 Apr;32(4):642-4; author reply 644. doi: 10.1097/PAS.0b013e31815b6056. No abstract available.

PMID:
18317354
19.

The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with "atypical glands suspicious for cancer".

He H, Magi-Galluzzi C, Li J, Carver P, Falzarano S, Smith K, Rubin MA, Zhou M.

Am J Surg Pathol. 2011 Apr;35(4):608-14. doi: 10.1097/PAS.0b013e31820bcd2d.

PMID:
21383613
Items per page

Supplemental Content

Write to the Help Desk